Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Precision Medicine in Refractory Cancer
NCT03089554Phase 2Recruiting
- Start
- Apr 2017
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in cancer. Primary endpoint: Progression-Free Survival at 2 years. Started Apr 2017; status: recruiting.
02
Conditions
cancer
Beyond the preview
Go deeper on NCT03089554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03089554.